Pipeline Therapeutics

Investigation into therapeutics for hidradenitis suppurativa (HS) has increased over the past two decades. As more is understood about HS pathogenesis, the number of drug targets has steadily risen. Neutrophils as well as the complement pathway have both been shown to contribute to HS pathogenesis and have become the focus of several ongoing clinical trials. Similarly, cytokines such as IL-17, IL-12/23, and IL1-α/β are being targeted for their suspected role in HS pathogenesis. Trials are also underway for small molecule inhibitors of the JAK/STAT pathway as well as anti-hormonal therapies and CD40 blockade. Beyond pharmaceuticals, there are also several surgical, procedural, and complementary and alternative practices currently being investigated. The future of HS looks bright as investigators continue to innovate and expand on HS management.